Kumamaru, Hiraku http://orcid.org/0000-0002-9759-6191
Kakeji, Yoshihiro
Fushimi, Kiyohide
Ishikawa, Koichi Benjamin
Yamamoto, Hiroyuki
Hashimoto, Hideki
Ono, Minoru
Iwanaka, Tadashi
Marubashi, Shigeru
Gotoh, Mitsukazu
Seto, Yasuyuki
Kitagawa, Yuko
Miyata, Hiroaki
Funding for this research was provided by:
Johnson and Johnson K.K.
National Clinical Database
Japan Agency for Medical Research and Development (16lk1010004h0002)
Article History
Received: 7 February 2022
Accepted: 30 March 2022
First Online: 24 May 2022
Declarations
:
: Dr. Kumamaru received speaker fees from Pfizer Japan Inc., Chugai Pharmaceutical Co., Ltd., and Johnson & Johnson K.K., and a consultation fee from Mitsubishi Tanabe Pharma Corporation. Dr. Yamamoto received a consultation fee from Mitsubishi Tanabe Pharma, a speaker fee from Chugai Pharmaceutical Co., Ltd., and Ono Pharmaceutical Co., Ltd., and payment for a manuscript from Astellas Pharma Inc. Drs. Kumamaru, Yamamoto, Iwanaka and Miyata are affiliated with the Department of Healthcare Quality Assessment at The University of Tokyo, which is a social collaboration department supported by the National Clinical Database, Johnson & Johnson K.K., and Nipro Corporation. Dr. Kitagawa reports receiving grants from CHUGAI PHARMACEUTICAL CO., LTD., TAIHO PHARMACEUTICAL CO., LTD, Yakult Honsha Co. Ltd., ASAHI KASEI PHARMA CORPORATION, Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., ONO PHARMACEUTICAL CO., LTD., TSUMURA & CO., Kyouwa Hakkou Kirin Co., Ltd., MEDICON INC., Eisai Co., Ltd., and Otsuka Pharmaceutical Factory Inc. Dr Kitagawa also discloses receiving personal fees from ONO PHARMACEUTICAL CO., LTD., and Bristol-Myers Squibb K.K., outside the submitted work. The other authors have no potential conflicts of interest to disclose.
: The study was reviewed and approved by the Institutional Review Board of the University of Tokyo Graduate School of Medicine and Faculty of Medicine (ID: 11467).
: An opt-out method was used for this observational study using preexisting medical information in the database. Participating facilities posted information about the use of clinical and administrative data for research purposes, and patients who chose not to participate were removed from the study database.
: NA.
: NA.